Een nieuwe rol voor radiotherapie: hoop voor mensen met levensbedreigende hartritmestoornissen
Straling redt levens, niet alleen bij kanker, maar ook bij dodelijke hartritmestoornissen. Eén hoge dosis gerichte straling op het hart kan het verschil maken tussen leven en plotse dood. Het klinkt bijna te mooi om waar te zijn, maar precies dat onderzoekt mijn thesis: hoe STAR (Stereotactic Arrhythmia Radioablation), een nieuwe radiotherapietechniek, hoop kan bieden in de strijd tegen plotse hartdood.
Elk jaar overlijden meer dan 800.000 Europeanen aan plotse hartdood. Ondanks decennia van vooruitgang blijven klassieke behandelingen zoals medicatie, implanteerbare defibrillatoren en katheterablatie tekortschieten bij een deel van de patiënten. Voor die groep kan STAR een nieuwe uitweg bieden: één gerichte dosis straling die levensbedreigende ritmestoornissen terugdringt zonder ingrijpende operatie.
Een nieuw perspectief voor hartpatiënten
Bij STAR dienen artsen in één sessie, één hoge dosis straling uiterst precies toe op het stukje hartweefsel dat de ritmestoornissen veroorzaakt. Een groot voordeel: dit gebeurt volledig niet-invasief. Waar een klassieke katheterablatie een ingrijpende operatie vereist, kunnen patiënten bij STAR al een halfuurtje later terug naar huis. Recente klinische studies lieten zien dat STAR levens kan redden, met een duidelijke afname van levensbedreigende ritmestoornissen na behandeling. Die resultaten zijn veelbelovend, maar toch blijven er twee onbeantwoorde vragen: hoe werkt STAR precies, en hoe veilig is het op lange termijn? Precies dat onderzoek ik.
Hoe werkt STAR?
Straling op het hart klinkt paradoxaal. Bij de behandeling van borst- of longkanker komt soms ook het omliggende weefsel, waaronder het hart, in het stralingsveld terecht, een bijwerking die artsen liever voorkomen. Uit die ervaring weten we dat bestraling van het hart op lange termijn schadelijke gevolgen kan veroorzaken, zoals littekenvorming of aderverkalking. Toch willen we dezelfde straling nu bewust gebruiken als therapie. Hoe kan dat?
Het antwoord ligt in de unieke aard van het hartweefsel én in de manier van bestralen. Tumorcellen delen razendsnel en zijn daardoor gevoelig voor herhaalde lage dosissen straling, verspreid over meerdere weken. Deze aanpak in kankerbehandeling beschadigt tumorcellen geleidelijk, waardoor de tumor uiteindelijk kleiner wordt. Hartcellen daarentegen delen nauwelijks en reageren dus heel anders. STAR werkt ook anders: één enkele, hoge dosis, uiterst precies gericht op een klein stukje ziek hartweefsel. Omdat de gevolgen van STAR grotendeels onbekend zijn, onderzocht ik welke veranderingen in het hart optreden na bestraling.
Van varkensmodel naar inzicht
Ik gebruikte een betrouwbaar varkensmodel omdat het varkenshart sterk lijkt op dat van de mens: bij de helft van de dieren lieten we hartritmestoornissen ontstaan, de andere helft bleef gezond. Beide groepen ondergingen STAR behandeling waarna wij ze wekenlang opvolgden met hartritmeregistratie en MRI-scans. Na tien weken analyseerden wij het hartweefsel volledig in het labo. Zo konden we zowel het ritme als de weefselreactie bestuderen.
Wat zagen we? De ritmestoornissen namen af na bestraling, een duidelijke bevestiging dat STAR werkt. Die bevindingen bracht ons vanzelf bij de centrale vraag: waarom werkt STAR?
Het snelle én het trage effect
Onderzoekers vermoeden dat STAR twee effecten heeft. Enerzijds een snel optredend effect: kort na bestraling lijkt de elektrische geleiding door het hart te verbeteren, alsof de bedrading wordt opgeschoond. Anderzijds is er mogelijks ook een laat optredend effect: weken tot maanden na bestraling verandert het weefsel langzaam, waardoor de bestraalde zones minder elektrisch actief worden en zo minder de signalen beïnvloeden.
De sleutelrol van fibroblasten
Dit laat optredende effect bracht ons bij één specifiek celtype: fibroblasten. Stel je ze voor als de bouwvakkers van het hart: ze liggen tussen de hartspiercellen en zorgen voor structuur en herstel door bindweefsel aan te maken. Bij schade of stress komen ze in actie om te herstellen, maar dat herstel kan soms ook té ver gaan en leiden tot littekenvorming. Over hun rol bij STAR was tot nu toe weinig bekend, maar ze worden gezien als mogelijke hoofdrolspelers in het laat optredend effect.
Tien weken na bestraling keken we of er al zichtbare weefselveranderingen waren. In het labo werden de harten grondig bestudeerd: met het blote oog zagen we geen nieuwe bindweefselvorming, en ook microscopisch vonden we geen duidelijke verschillen in bindweefsel tussen hoge en lage doses bestraling. Toch waren de bouwvakkers al druk in de weer: vier bekende markers van fibroblastactivatie waren verhoogd. Dit betekende dat deze cellen hun gereedschap al klaarlegden, ze bereiden zich voor op het aanmaken van nieuw bindweefsel. Ook de bijbehorende activatie-eiwitten, de eerste materialen die klaarliggen op de werf, werden al in grote hoeveelheden geproduceerd. Deze observaties bevestigen een vroeg stadium van fibroblastactivatie tien weken na STAR, nog vóór zichtbare bindweefselvorming.
Dat maakt dit onderzoek bijzonder: het is de éérste keer dat experimentele data dit laat optredend effect van STAR ondersteunen. Wat tot nu toe een hypothese was, konden we hier voor het eerst in actie zien.
Hoe veilig is STAR?
Naast het begrijpen van de werking is het minstens even belangrijk om de veiligheid te evalueren. De dieren werden tien weken gevolgd met MRI-scans en gezondheidsmetingen. In het algemeen bleven hartfunctie en gezondheid stabiel. Tegelijkertijd zagen we subtiele veranderingen zoals vochtophoping en kleine bloedingen. Deze bleven lokaal en leidden niet tot functieverlies van het hart. Of ze op lange termijn invloed zullen hebben, weten we nog niet. Daarmee tonen onze resultaten dat STAR op korte termijn goed verdragen wordt, maar dat de veiligheid op langere termijn verder onderzocht moet worden.
Samengevat is STAR een veelbelovende, niet-invasieve optie voor patiënten met hardnekkige hartritmestoornissen. Mijn studie levert het eerste bewijs dat naast een snel optredend effect ook laat optredende weefseleffecten in gang gezet worden. Of dit uiteindelijk de ritmestoornissen blijvend onderdrukt, moeten toekomstige studies bewijzen. Maar één ding is duidelijk: deze eerste blik op fibroblasten geeft ons een sleutel om het mysterie van STAR verder te ontrafelen. Zo zetten we een belangrijke stap naar een toekomst waarin straling niet alleen kanker, maar ook dodelijke hartritmestoornissen kan bestrijden.
Bibliografie
1. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. Vol. 80, Journal of the American College of Cardiology. 2022.
2. Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. Vol. 74, Journal of the American College of Cardiology. 2019.
3. World Health Organization (WHO). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). 2021. Cardiovascular diseases (CVDs).
4. Zeppenfeld K, Tfelt-Hansen J, De Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Vol. 43, European Heart Journal. 2022.
5. Zipes DP, Wellens HJJ. Sudden cardiac death. Vol. 98, Circulation. 1998.
6. De Vreede-Swagemakers JJM, Gorgels APM, Dubois-Arbouw WI, Van Ree JW, Daemen MJAP, Houben LGE, et al. Out-of-hospital cardiac arrest in the 1990s: A population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997;30(6).
7. Lynge TH, Risgaard B, Banner J, Nielsen JL, Jespersen T, Stampe NK, et al. Nationwide burden of sudden cardiac death: A study of 54,028 deaths in Denmark. Heart Rhythm. 2021 Oct;18(10):1657–65.
8. Kumar A, Avishay DM, Jones CR, Shaikh JD, Kaur R, Aljadah M, et al. Sudden cardiac death: epidemiology, pathogenesis and management. Rev Cardiovasc Med [Internet]. 2021 Mar 1 [cited 2024 Sep 29];22(1):147–58. Available from: https://pubmed.ncbi.nlm.nih.gov/33792256/
9. Proietti R, Joza J, Essebag V. Therapy for ventricular arrhythmias in structural heart disease: A multifaceted challenge. Journal of Physiology. 2016;594(9).
10. Jumeau R, Ozsahin M, Schwitter J, Elicin O, Reichlin T, Roten L, et al. Stereotactic Radiotherapy for the Management of Refractory Ventricular Tachycardia: Promise and Future Directions. Vol. 7, Frontiers in Cardiovascular Medicine. 2020.
11. Larson J, Rich L, Deshmukh A, Judge EC, Liang JJ. Pharmacologic Management for Ventricular Arrhythmias: Overview of Anti-Arrhythmic Drugs. Vol. 11, Journal of Clinical Medicine. 2022.
12. Balaji P, Liulu X, Sivakumar S, Chong JJH, Kizana E, Vandenberg JI, et al. Mechanistic Insights and Knowledge Gaps in the Effects of Radiation Therapy on Cardiac Arrhythmias. Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):75–89.
13. Wang S, Luo H, Mao T, Xiang C, Hu H, Zhao J, et al. Stereotactic arrhythmia radioablation: A novel therapy for cardiac arrhythmia. Vol. 20, Heart Rhythm. 2023.
14. Shangguan W, Xu G, Wang X, Zhang N, Liu X, Li G, et al. Stereotactic Radiotherapy: An Alternative Option for Refractory Ventricular Tachycardia to Drug and Ablation Therapy. Vol. 11, Journal of Clinical Medicine. 2022.
15. Thawkar VN, Taksande K. A Comprehensive Review on Stereotactic Arrhythmia Radioablation (STAR): Pioneering a New Era in Arrhythmia Management. Cureus. 2024 Oct;16(10):e70601.
16. Zhang S, Hu L, Tang H, Liao L, Li X. Stereotactic arrhythmia radioablation (STAR) opens a new era in the treatment of arrhythmias? Front Cardiovasc Med. 2024 Sep 27;11.
17. Kohajda Z, Loewe A, Tóth N, Varró A, Nagy N. The Cardiac Pacemaker Story—Fundamental Role of the Na+/Ca2+ Exchanger in Spontaneous Automaticity. Vol. 11, Frontiers in Pharmacology. 2020.
18. Fye WB. The origin of the heart beat: A tale of frogs, jellyfish, and turtles. Circulation. 1987;76(3).
19. Peters CH, Sharpe EJ, Proenza C. Cardiac Pacemaker Activity and Aging. Vol. 82, Annual Review of Physiology. 2020.
20. Keith A, Flack M. The Form and Nature of the Muscular Connections between the Primary Divisions of the Vertebrate Heart. J Anat Physiol. 1907;41(Pt 3).
21. MacDonald EA, Rose RA, Quinn TA. Neurohumoral Control of Sinoatrial Node Activity and Heart Rate: Insight From Experimental Models and Findings From Humans. Vol. 11, Frontiers in Physiology. 2020.
22. Richard E. Klabunde P. Sinoatrial Node Action Potentials. Cardiovascular Physiology Concepts. 2023 Oct 27;
23. Boron WF, Boulpaep EL. Boron and Boulpaep Medical Physiology. In: Medical Physiology. 2012.
24. Mangoni ME, Nargeot J. Genesis and regulation of the heart automaticity. Vol. 88, Physiological Reviews. 2008.
25. Saffitz JE, Schuessler RB, Yamada KA. Mechanisms of remodeling of gap junction distributions and the development of anatomic substrates of arrhythmias. Vol. 42, Cardiovascular Research. 1999.
26. Basu I, Li H, Trease AJ, Sorgen PL. Regulation of Cx43 Gap Junction Intercellular Communication by Bruton’s Tyrosine Kinase and Interleukin-2-Inducible T-Cell Kinase. Biomolecules. 2023;13(4).
27. Kingma J, Simard C, Drolet B. Overview of Cardiac Arrhythmias and Treatment Strategies. Vol. 16, Pharmaceuticals. 2023.
28. Zhou M, Zheng M, Zhou X, Tian S, Yang X, Ning Y, et al. The roles of connexins and gap junctions in the progression of cancer. Vol. 21, Cell Communication and Signaling. 2023.
29. Severs NJ, Coppen SR, Dupont E, Yeh HI, Ko YS, Matsushita T. Gap junction alterations in human cardiac disease. Vol. 62, Cardiovascular Research. 2004.
30. Kanno S, Saffitz JE. The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Vol. 10, Cardiovascular Pathology. 2001.
31. Lerner DL, Beardslee MA, Saffitz JE. The role of altered intercellular coupling in arrhythmias induced by acute myocardial ischemia. Vol. 50, Cardiovascular Research. 2001.
32. MacLeod K. An Essential Introduction To Cardiac Electrophysiology. An Essential Introduction to Cardiac Electrophysiology. 2013.
33. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002 Jan 10;415(6868):198–205.
34. de Bakker JMT, van Rijen HVM. Cardiac Action Potentials, Ion Channels, and Gap Junctions. In: Cardiac Electrophysiology Methods and Models. 2010.
35. Chrysafides SM, Bordes SJ, Sharma S. Physiology, Resting Potential. StatPearls. 2023;
36. Hille B. Ion channels of excitable membranes. 3rd ed. Sunderland, Massachusetts: Sinauer Associates, Inc.; 2001. 1–22 p.
37. Terlau H, Stühmer W. Structure and function of voltage-gated ion channels. Vol. 85, Naturwissenschaften. 1998.
38. Kansakar U, Varzideh F, Jankauskas SS, Gambardella J, Trimarco B, Santulli G. Advances in the understanding of excitation-contraction coupling: The pulsing quest for drugs against heart failure and arrhythmias. Vol. 7, European Heart Journal - Cardiovascular Pharmacotherapy. 2021.
39. Kurihara S, Fukuda N. Regulation of myocardial contraction as revealed by intracellular Ca2+ measurements using aequorin. Vol. 74, The journal of physiological sciences : JPS. 2024.
40. Marks AR. Calcium and the heart: A question of life and death. Vol. 111, Journal of Clinical Investigation. 2003.
41. Macintosh BR, Holash RJ, Renaud JM. Skeletal muscle fatigue-regulation of excitation-contraction coupling to avoid metabolic catastrophe. J Cell Sci. 2012;125(9).
42. Eisner DA, Caldwell JL, Kistamás K, Trafford AW. Calcium and Excitation-Contraction Coupling in the Heart. Vol. 121, Circulation Research. 2017.
43. Morano I. The Contractile Machines of the Heart. Adv Exp Med Biol. 2024;1441:417–33.
44. Tallquist MD. Cardiac Fibroblast Diversity. Vol. 82, Annual Review of Physiology. 2020.
45. Fahrenbach JP, Mejia-Alvarez R, Banach K. The relevance of non-excitable cells for cardiac pacemaker function. Journal of Physiology. 2007;585(2).
46. Zaglia T, Bona A Di, Mongillo M. A light wand to untangle the myocardial cell network. Vol. 2, Methods and Protocols. 2019.
47. Goldsmith EC, Hoffman A, Morales MO, Potts JD, Price RL, McFadden A, et al. Organization of fibroblasts in the heart. Developmental Dynamics. 2004;230(4).
48. Litviňuková M, Talavera-López C, Maatz H, Reichart D, Worth CL, Lindberg EL, et al. Cells of the adult human heart. Nature. 2020;588(7838).
49. Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT, D’antoni ML, Debuque R, et al. Revisiting cardiac cellular composition. Circ Res. 2016;118(3).
50. Daseke MJ, Tenkorang MAA, Chalise U, Konfrst SR, Lindsey ML. Cardiac fibroblast activation during myocardial infarction wound healing: Fibroblast polarization after MI. Matrix Biology. 2020;91–92.
51. Eghbali M, Weber KT. Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem. 1990;96(1).
52. Mahoney VM, Mezzano V, Morley GE. A review of the literature on cardiac electrical activity between fibroblasts and myocytes. Prog Biophys Mol Biol. 2016;120(1–3).
53. Cakir SN, Whitehead KM, Hendricks HKL, de Castro Brás LE. Novel Techniques Targeting Fibroblasts after Ischemic Heart Injury. Vol. 11, Cells. 2022.
54. Hall C, Gehmlich K, Denning C, Pavlovic D. Complex relationship between cardiac fibroblasts and cardiomyocytes in health and disease. J Am Heart Assoc. 2021;10(5).
55. Harrington A, Moore-Morris T. Cardiac fibroblasts in heart failure and regeneration. Front Cell Dev Biol. 2024;12.
56. Kleinbongard P, Senyo SE, Lindsey ML, Garvin AM, Simpson JA, de Castro Brás LE. Cardiac Fibroblasts: Answering the Call. Am J Physiol Heart Circ Physiol. 2024 Aug 14;1–16.
57. Zhang Z, Yang Z, Wang S, Wang X, Mao J. Targeting MAPK-ERK/JNK pathway: A potential intervention mechanism of myocardial fibrosis in heart failure. Vol. 173, Biomedicine and Pharmacotherapy. 2024.
58. Dostal D, Glaser S, Baudino TA. Cardiac fibroblast physiology and pathology. Compr Physiol. 2015;5(2).
59. Miragoli M, Salvarani N, Rohr S. Myofibroblasts induce ectopic activity in cardiac tissue. Circ Res. 2007;101(8).
60. Vasquez C, Benamer N, Morley GE. The cardiac fibroblast: Functional and electrophysiological considerations in healthy and diseased hearts. Vol. 57, Journal of Cardiovascular Pharmacology. 2011.
61. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Vol. 65, Cardiovascular Research. 2005.
62. McNair BD, Shorthill SK, Bruns DR. More than just a small left ventricle: the right ventricular fibroblast and ECM in health and disease. Vol. 325, American Journal of Physiology - Endocrinology and Metabolism. 2023.
63. Ali SR, Ranjbarvaziri S, Talkhabi M, Zhao P, Subat A, Hojjat A, et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ Res. 2014;115(7).
64. Skelly DA, Squiers GT, McLellan MA, Bolisetty MT, Robson P, Rosenthal NA, et al. Single-Cell Transcriptional Profiling Reveals Cellular Diversity and Intercommunication in the Mouse Heart. Cell Rep. 2018;22(3).
65. Farbehi N, Patrick R, Dorison A, Xaymardan M, Janbandhu V, Wystub-Lis K, et al. Single-cell expression profiling reveals dynamic flux of cardiac stromal, vascular and immune cells in health and injury. Elife. 2019;8.
66. Amoni M, Dries E, Ingelaere S, Vermoortele D, Roderick HL, Claus P, et al. Ventricular arrhythmias in ischemic cardiomyopathy—New avenues for mechanism-guided treatment. Vol. 10, Cells. 2021.
67. Severino P, D’amato A, Pucci M, Infusino F, Adamo F, Birtolo LI, et al. Ischemic heart disease pathophysiology paradigms overview: From plaque activation to microvascular dysfunction. Vol. 21, International Journal of Molecular Sciences. 2020.
68. Mayo Clinic Staff. mayoclinic.org. 2024. Arteriosclerosis / atherosclerosis.
69. Crea F, Camici PG, Merz CNB. Coronary microvascular dysfunction: An update. Vol. 35, European Heart Journal. 2014.
70. Gusev E, Sarapultsev A. Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes. Vol. 24, International Journal of Molecular Sciences. 2023.
71. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Vol. 108, Circulation. 2003.
72. Stone PH, Libby P, Boden WE. Fundamental Pathobiology of Coronary Atherosclerosis and Clinical Implications for Chronic Ischemic Heart Disease Management - The Plaque Hypothesis: A Narrative Review. Vol. 8, JAMA Cardiology. 2023.
73. Marzilli M, Merz CNB, Boden WE, Bonow RO, Capozza PG, Chilian WM, et al. Obstructive coronary atherosclerosis and ischemic heart disease: An elusive link! Vol. 60, Journal of the American College of Cardiology. 2012.
74. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/24825-vasospasm. 2023. Vasospasm.
75. Rehan R, Yong A, Ng M, Weaver J, Puranik R. Coronary microvascular dysfunction: A review of recent progress and clinical implications. Vol. 10, Frontiers in Cardiovascular Medicine. 2023.
76. Van Den Borne SWM, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: The role of myofibroblasts. Vol. 7, Nature Reviews Cardiology. 2010.
77. Ravassa S, López B, Treibel TA, San José G, Losada-Fuentenebro B, Tapia L, et al. Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies. Vol. 93, Molecular Aspects of Medicine. 2023.
78. Frangogiannis NG. Cardiac fibrosis. Vol. 117, Cardiovascular Research. 2021.
79. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Vol. 10, Nature Reviews Cardiology. 2013.
80. Hinderer S, Schenke-Layland K. Cardiac fibrosis – A short review of causes and therapeutic strategies. Vol. 146, Advanced Drug Delivery Reviews. 2019.
81. Amoni M, Vermoortele D, Ekhteraei-Tousi S, Doñate Puertas R, Gilbert G, Youness M, et al. Heterogeneity of Repolarization and Cell-Cell Variability of Cardiomyocyte Remodeling Within the Myocardial Infarction Border Zone Contribute to Arrhythmia Susceptibility. Circ Arrhythm Electrophysiol. 2023;16(5).
82. Zhang Y, Kanter EM, Yamada KA. Remodeling of cardiac fibroblasts following myocardial infarction results in increased gap junction intercellular communication. Cardiovascular Pathology. 2010;19(6).
83. Chilton L, Giles WR, Smith GL. Evidence of intercellular coupling between co-cultured adult rabbit ventricular myocytes and myofibroblasts. Journal of Physiology. 2007;583(1).
84. Chen YC, Shih CL, Wu CL, Fang YH, So EC, Wu SN. Exploring the Impact of BKCa Channel Function in Cellular Membranes on Cardiac Electrical Activity. Vol. 25, International Journal of Molecular Sciences. 2024.
85. Bräuninger H, Thottakara T, Schön J, Voss S, Dhople V, Warnke S, et al. Cytokine-mediated alterations of human cardiac fibroblast’s secretome. Int J Mol Sci. 2021;22(22).
86. Bolívar S, Anfossi R, Humeres C, Vivar R, Boza P, Muñoz C, et al. IFN-β plays both pro- and anti-inflammatory roles in the rat cardiac fibroblast through differential STAT protein activation. Front Pharmacol. 2018;9(NOV).
87. Thottakara T, Dhople VM, Voss S, Schoen J, Voelker U, Blankenberg S, et al. The Cardiac Fibroblast in heart failure – an inflammatory cell. Eur Heart J. 2020;41(Supplement_2).
88. Isidoro Tavares N, Philip-Couderc P, Baertschi AJ, Lerch R, Montessuit C. Angiotensin II and tumour necrosis factor α as mediators of ATP-dependent potassium channel remodelling in post-infarction heart failure. Cardiovasc Res. 2009;83(4).
89. Baudino TA, Carver W, Giles W, Borg TK. Cardiac fibroblasts: Friend or foe? Vol. 291, American Journal of Physiology - Heart and Circulatory Physiology. 2006.
90. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Vol. 110, Circulation Research. 2012.
91. Daseke MJ, Chalise U, Becirovic-Agic M, Salomon JD, Cook LM, Case AJ, et al. Neutrophil signaling during myocardial infarction wound repair. Vol. 77, Cellular Signalling. 2021.
92. Ma Y, Mouton AJ, Lindsey ML. Cardiac macrophage biology in the steady-state heart, the aging heart, and following myocardial infarction. Vol. 191, Translational Research. 2018.
93. Hadebe N, Cour M, Lecour S. The SAFE pathway for cardioprotection: is this a promising target? Basic Res Cardiol. 2018;113(2).
94. Rossello X, Yellon DM. The RISK pathway and beyond. Vol. 113, Basic Research in Cardiology. 2018.
95. Jackson BM, Gorman JH, Salgo IS, Moainie SL, Plappert T, St. John-sutton M, et al. Border zone geometry increases wall stress after myocardial infarction: Contrast echocardiographic assessment. Am J Physiol Heart Circ Physiol. 2003;284(2 53-2).
96. Ashikaga H, Mickelsen SR, Ennis DB, Rodriguez I, Kellman P, Wen H, et al. Electromechanical analysis of infarct border zone in chronic myocardial infarction. Am J Physiol Heart Circ Physiol. 2005;289(3 58-3).
97. Hegyi B, Bossuyt J, Griffiths LG, Shimkunas R, Coulibaly Z, Jian Z, et al. Complex electrophysiological remodeling in postinfarction ischemic heart failure. Proc Natl Acad Sci U S A. 2018;115(13).
98. Cluitmans MJM, Bayer J, Bear LR, ter Bekke RMA, Heijman J, Coronel R, et al. The circle of reentry: Characteristics of trigger-substrate interaction leading to sudden cardiac arrest. Front Cardiovasc Med [Internet]. 2023 [cited 2024 Oct 28];10. Available from: https://pubmed.ncbi.nlm.nih.gov/37139119/
99. Liu MB, De Lange E, Garfinkel A, Weiss JN, Qu Z. Delayed afterdepolarizations generate both triggers and a vulnerable substrate promoting reentry in cardiac tissue. Heart Rhythm. 2015;12(10).
100. Bogun F, Crawford T, Chalfoun N, Kuhne M, Sarrazin JF, Wells D, et al. Relationship of frequent postinfarction premature ventricular complexes to the reentry circuit of scar-related ventricular tachycardia. Heart Rhythm. 2008;5(3).
101. De Bakker JMT, Van Capelle FJL, Janse MJ, Tasseron S, Vermeulen JT, De Jonge N, et al. Slow conduction in the infarcted human heart: “Zigzag” course of activation. Circulation. 1993;88(3).
102. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Bloma N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Vol. 36, European Heart Journal. 2015.
103. Van Welsenes GH, Van Rees JB, Borleffs CJW, Cannegieter SC, Bax JJ, Van Erven L, et al. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace. 2011;13(3).
104. Van Der Heijden AC, Borleffs CJW, Buiten MS, Thijssen J, Van Rees JB, Cannegieter SC, et al. The clinical course of patients with implantable cardioverter-defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications. Heart Rhythm. 2015;12(6).
105. Proietti R, Labos C, Davis M, Thanassoulis G, Santangeli P, Russo V, et al. A Systematic Review and Meta-analysis of the Association Between Implantable Cardioverter-Defibrillator Shocks and Long-term Mortality. Vol. 31, Canadian Journal of Cardiology. 2015.
106. Back SH, Kowey PR. Strategies to reduce recurrent shocks due to ventricular arrhythmias in patients with an implanted cardioverter-defibrillator. Arrhythm Electrophysiol Rev. 2019;8(2).
107. Ponti R De. Role of catheter ablation of ventricular tachycardia associated with structural heart disease. World J Cardiol. 2011;3(11).
108. Natale A, Zeppenfeld K, Della Bella P, Liu X, Sabbag A, Santangeli P, et al. Twenty-five years of catheter ablation of ventricular tachycardia: A look back and a look forward. Vol. 25, Europace. 2023.
109. Aliot EM, Stevenson WG, Almendral-Garrote JM, Bogun F, Calkins CH, Delacretaz E, et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm. 2009 Jun;6(6):886–933.
110. Tilz RR, Lin T, Eckardt L, Deneke T, Andresen D, Wieneke H, et al. Ablation Outcomes and Predictors of Mortality Following Catheter Ablation for Ventricular Tachycardia: Data From the German Multicenter Ablation Registry. J Am Heart Assoc. 2018;7(6).
111. Jadczyk T, Miszczyk M, Kurzelowski R, Latusek T, Bednarek J, Golba KS, et al. Stereotactic Radioablation for Treatment of Ventricular Tachycardia. In: Innovative Treatment Strategies for Clinical Electrophysiology. Springer; 2022. p. 1–27.
112. Qian PC, Azpiri JR, Assad J, Gonzales Aceves EN, Cardona Ibarra CE, de la Pena C, et al. Noninvasive stereotactic radioablation for the treatment of atrial fibrillation: First-in-man experience. J Arrhythm. 2020;36(1).
113. Lee J, Bates M, Shepherd E, Riley S, Henshaw M, Metherall P, et al. Cardiac stereotactic ablative radiotherapy for control of refractory ventricular tachycardia: Initial UK multicentre experience. Open Heart. 2021;8(2).
114. Loo BW, Soltys SG, Wang L, Lo A, Fahimian BP, Iagaru A, et al. Stereotactic Ablative Radiotherapy for the Treatment of Refractory Cardiac Ventricular Arrhythmia. Circ Arrhythm Electrophysiol. 2015;8(3).
115. Qian PC, Quadros K, Aguilar M, Wei C, Boeck M, Bredfeldt J, et al. Substrate Modification Using Stereotactic Radioablation to Treat Refractory Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy. JACC Clin Electrophysiol. 2022;8(1).
116. Cuculich PS, Schill MR, Kashani R, Mutic S, Lang A, Cooper D, et al. Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia. New England Journal of Medicine. 2017;377(24).
117. Robinson CG, Samson PP, Moore KMS, Hugo GD, Knutson N, Mutic S, et al. Phase I/II Trial of Electrophysiology-Guided Noninvasive Cardiac Radioablation for Ventricular Tachycardia. Circulation. 2019;139(3).
118. Miszczyk M, Jadczyk T, Gołba K, Wojakowski W, Wita K, Bednarek J, et al. Clinical evidence behind stereotactic radiotherapy for the treatment of ventricular tachycardia (Star)—a comprehensive review. Vol. 10, Journal of Clinical Medicine. 2021.
119. Lewis GD, Farach A. Cardiovascular Toxicities of Radiation Therapy. Vol. 15, Methodist DeBakey Cardiovascular Journal. 2019.
120. Nabiałek-Trojanowska I, Lewicka E, Wrona A, Kaleta AM, Lewicka-Potocka Z, Raczak G, et al. Cardiovascular complications after radiotherapy. Vol. 27, Cardiology Journal. 2020.
121. Cozzi S, Alì E, Bardoscia L, Najafi M, Botti A, Blandino G, et al. Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review. Vol. 14, Cancers. 2022.
122. Paoletti L, Ceccarelli C, Menichelli C, Aristei C, Borghesi S, Tucci E, et al. Special stereotactic radiotherapy techniques: procedures and equipment for treatment simulation and dose delivery. Vol. 27, Reports of Practical Oncology and Radiotherapy. 2022.
123. Cozzi S, Bottoni N, Botti A, Trojani V, Alì E, Finocchi Ghersi S, et al. The Use of Cardiac Stereotactic Radiation Therapy (SBRT) to Manage Ventricular Tachycardia: A Case Report, Review of the Literature and Technical Notes. J Pers Med. 2022;12(11).
124. Ringborg U, Bergqvist D, Brorsson B, Cavallin-Ståhl E, Ceberg J, Einhorn N, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001--summary and conclusions. Acta Oncol. 2003;42(5–6):357–65.
125. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: Current advances and future directions. Vol. 9, International Journal of Medical Sciences. 2012.
126. Narayanan S J J, Tripathi D, Verma P, Adhikary A, Dutta AK. Secondary Electron Attachment-Induced Radiation Damage to Genetic Materials. Vol. 8, ACS Omega. 2023.
127. Hanahan D. Hallmarks of Cancer: New Dimensions. Vol. 12, Cancer Discovery. 2022.
128. Sia J, Szmyd R, Hau E, Gee HE. Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer. Vol. 8, Frontiers in Cell and Developmental Biology. 2020.
129. Whitaker J, Zei PC, Ahmad S, Niederer S, O’Neill M, Rinaldi CA. The effect of ionizing radiation through cardiac stereotactic body radiation therapy on myocardial tissue for refractory ventricular arrhythmias: A review. Vol. 9, Frontiers in Cardiovascular Medicine. 2022.
130. Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, et al. Chemotherapy and radiotherapy: Cryptic anticancer vaccines. Vol. 22, Seminars in Immunology. 2010.
131. Narowska G, Gandhi S, Tzeng A, Hamad EA. Cardiovascular Toxicities of Radiation Therapy and Recommended Screening and Surveillance. Vol. 10, Journal of Cardiovascular Development and Disease. 2023.
132. Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, et al. Radiation-Related Heart Disease: Current Knowledge and Future Prospects. Vol. 76, International Journal of Radiation Oncology Biology Physics. 2010.
133. Haque R, Prout M, Geiger AM, Kamineni A, Thwin SS, Avila C, et al. Comorbidities and cardiovascular disease risk in older breast cancer survivors. American Journal of Managed Care. 2014;20(1).
134. Hooning MJ, Botma A, Aleman BMP, Baaijens MHA, Bartelink H, Klijn JGM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5).
135. Shah C, Badiyan S, Berry S, Khan AJ, Goyal S, Schulte K, et al. Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy. Vol. 112, Radiotherapy and Oncology. 2014.
136. Akdag O, Borman PTS, Mandija S, Woodhead PL, Uijtewaal P, Raaymakers BW, et al. Experimental demonstration of real-time cardiac physiology-based radiotherapy gating for improved cardiac radioablation on an MR-linac. Med Phys. 2024;51(4).
137. Spartalis M, Spartalis E, Athanasiou A, Nikiteas N. Safety concerns regarding ablative radiotherapy for ventricular tachycardia. Vol. 128, Radiotherapy and Oncology. 2018.
138. Sharma A, Wong D, Weidlich G, Fogarty T, Jack A, Sumanaweera T, et al. Noninvasive stereotactic radiosurgery (CyberHeart) for creation of ablation lesions in the atrium. Heart Rhythm. 2010;7(6).
139. Maguire PJ, Gardner E, Jack AB, Zei P, Al-Ahmad A, Fajardo L, et al. Cardiac Radiosurgery (CyberHeartTM) for Treatment of Arrhythmia: Physiologic and Histopathologic Correlation in the Porcine Model. Cureus. 2012;
140. Blanck O, Bode F, Gebhard M, Hunold P, Brandt S, Bruder R, et al. Dose-escalation study for cardiac radiosurgery in a porcine model. Int J Radiat Oncol Biol Phys. 2014;89(3).
141. Hayase J, Chin R, Cao M, Hu P, Shivkumar K, Bradfield JS. Non-invasive Stereotactic Body Radiation Therapy for Refractory Ventricular Arrhythmias: Venturing into the Unknown. Vol. 13, Journal of Innovations in Cardiac Rhythm Management. 2022.
142. Cha MJ, Seo JW, Kim HJ, Kim MK, Yoon HS, Jo SW, et al. Early changes in rat heart after high-dose irradiation: Implications for antiarrhythmic effects of cardiac radioablation. J Am Heart Assoc. 2021;10(6).
143. Kiani S, Kutob L, Schneider F, Higgins KA, Lloyd MS. Histopathologic and Ultrastructural Findings in Human Myocardium After Stereotactic Body Radiation Therapy for Recalcitrant Ventricular Tachycardia. Circ Arrhythm Electrophysiol. 2020;13(11).
144. Zhang DM, Navara R, Yin T, Szymanski J, Goldsztejn U, Kenkel C, et al. Cardiac radiotherapy induces electrical conduction reprogramming in the absence of transmural fibrosis. Nat Commun. 2021;12(1).
145. SHAW RM, RUDY Y. The Vulnerable Window for Unidirectional Block in Cardiac Tissue: Characterization and Dependence on Membrane Excitability and Intercellular Coupling. J Cardiovasc Electrophysiol. 1995;6(2).
146. Nguyen TP, Qu Z, Weiss JN. Cardiac fibrosis and arrhythmogenesis: The road to repair is paved with perils. Vol. 70, Journal of Molecular and Cellular Cardiology. 2014.
147. Rapp F, Simoniello P, Wiedemann J, Bahrami K, Grünebaum V, Ktitareva S, et al. Biological Cardiac Tissue Effects of High-Energy Heavy Ions - Investigation for Myocardial Ablation. Sci Rep. 2019 Mar 21;9(1):5000.
148. Shah KD, Chang CW, Tian S, Patel P, Qiu R, Roper J, et al. Evaluating the Efficacy and Safety of Stereotactic Arrhythmia Radioablation in Ventricular Tachycardia: A Comprehensive Systematic Review and Meta-Analysis. ArXiv. 2025 Jan 31;
149. Kim BH, Jung JW, Han D, Cha MJ, Chang JH. One-Week Dynamic Changes in Cardiac Proteomes After Cardiac Radioablation in Experimental Rat Model. Front Cardiovasc Med. 2022;9.
150. Amino M, Yamazaki M, Yoshioka K, Kawabe N, Tanaka S, Shimokawa T, et al. Heavy Ion Irradiation Reduces Vulnerability to Atrial Tachyarrhythmias - Gap Junction and Sympathetic Neural Remodeling. Circulation Journal. 2023;87(7).
151. Amino M, Yoshioka K, Furusawa Y, Tanaka S, Kawabe N, Hashida T, et al. Inducibility of Ventricular Arrhythmia 1 Year Following Treatment with Heavy Ion Irradiation in Dogs with Myocardial Infarction. PACE - Pacing and Clinical Electrophysiology. 2017;40(4).
152. Amoni M, Claus P, Dries E, Nagaraju C, De Buck S, Vandenberk B, et al. Discrete sites of frequent premature ventricular complexes cluster within the infarct border zone and coincide with high frequency of delayed afterdepolarizations under adrenergic stimulation. Heart Rhythm. 2021;18(11).
153. Amoni M, Ingelaere S, Moeyersons J, Wets D, Tanushi A, Van Huffel S, et al. Regional beat-to-beat variability of repolarization increases during ischemia and predicts imminent arrhythmias in a pig model of myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology. 2023 Jul 1;325(1):H54–65.
154. Smith AC, Swindle M. Anesthesia and Analgesia in Swine. In: Anesthesia and Analgesia in Laboratory Animals. 2008.
155. Steffel J, Wright DJ, Schäfer H, Rashid-Fadel T, Lewalter T. Insertion of miniaturized cardiac monitors outside the catheter operating room: Experience and practical advice. Vol. 19, Europace. 2017.
156. Wu M, Bogaert J, D’Hooge J, Sipido K, Maes F, Dymarkowski S, et al. Closed-chest animal model of chronic coronary artery stenosis. Assessment with magnetic resonance imaging. International Journal of Cardiovascular Imaging. 2010;26(3).
157. Xie F, Xiao P, Chen D, Xu L, Zhang B. miRDeepFinder: A miRNA analysis tool for deep sequencing of plant small RNAs. Plant Mol Biol. 2012;80(1).
158. Landini G, Martinelli G, Piccinini F. Colour deconvolution: Stain unmixing in histological imaging. Vol. 37, Bioinformatics. 2021.
159. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10).
160. Dreyfuss AD, Velalopoulou A, Avgousti H, Bell BI, Verginadis II. Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers. Vol. 12, Frontiers in Oncology. 2022.
161. Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: mechanisms and implications for therapy. Vol. 141, Journal of Cancer Research and Clinical Oncology. 2015.
162. Fu X, Khalil H, Kanisicak O, Boyer JG, Vagnozzi RJ, Maliken BD, et al. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. Journal of Clinical Investigation. 2018;128(5).
163. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction. Vol. 119, Circulation Research. 2016.
164. Cleutjens JPM, Verluyten MJA, Smits JFM, Daemen MJAP. Collagen remodeling after myocardial infarction in the rat heart. American Journal of Pathology. 1995;147(2).
165. Nagaraju CK, Dries E, Popovic N, Singh AA, Haemers P, Roderick HL, et al. Global fibroblast activation throughout the left ventricle but localized fibrosis after myocardial infarction. Sci Rep. 2017;7(1).
166. Scalise RFM, De Sarro R, Caracciolo A, Lauro R, Squadrito F, Carerj S, et al. Fibrosis after Myocardial Infarction: An Overview on Cellular Processes, Molecular Pathways, Clinical Evaluation and Prognostic Value. Vol. 9, Medical sciences (Basel, Switzerland). 2021.
167. He S, Sharpless NE. Senescence in Health and Disease. Vol. 169, Cell. 2017.
168. Schafer MJ, White TA, Iijima K, Haak AJ, Ligresti G, Atkinson EJ, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. 2017;8.
169. Nguyen HQ, To NH, Zadigue P, Kerbrat S, De La Taille A, Le Gouvello S, et al. Ionizing radiation-induced cellular senescence promotes tissue fibrosis after radiotherapy. A review. Vol. 129, Critical Reviews in Oncology/Hematology. 2018.
170. Zhu F, Li Y, Zhang J, Piao C, Liu T, Li HH, et al. Senescent cardiac fibroblast is critical for cardiac fibrosis after myocardial infarction. PLoS One. 2013;8(9).
171. Snider P, Standley KN, Wang J, Azhar M, Doetschman T, Conway SJ. Origin of cardiac fibroblasts and the role of periostin. Vol. 105, Circulation Research. 2009.
172. Sharma UC, Sonkawade SD, Spernyak JA, Sexton S, Nguyen J, Dahal S, et al. A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy. Circ Heart Fail. 2018;11(8).
173. Kancharla K, Olson A, Salavatian S, Kuwabara Y, Martynyuk Y, Dutta P, et al. Ventricular arrhythmia inducibility in porcine infarct model after stereotactic body radiation therapy. Heart Rhythm. 2024;21(7).
174. Airaksinen J, Siimes S, Hartikainen J, Ylä-Herttuala S. Long-term continuous monitoring of arrhythmias in pigs with insertable cardiac monitors. Pflugers Arch. 2024 Jul;476(7):1145–54.
175. Barazzuol L, Coppes RP, van Luijk P. Prevention and treatment of radiotherapy-induced side effects. Vol. 14, Molecular Oncology. 2020.
176. Mee T, Kirkby NF, Defourny NN, Kirkby KJ, Burnet NG. The use of radiotherapy, surgery and chemotherapy in the curative treatment of cancer: results from the FORTY (Favourable Outcomes from RadioTherapY) project. British Journal of Radiology. 2023;96(1152).
177. Van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, et al. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16).
178. Raghunathan D, Khilji MI, Hassan SA, Yusuf SW. Radiation-Induced Cardiovascular Disease. Vol. 19, Current Atherosclerosis Reports. 2017.
179. Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, et al. Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. Journal of Clinical Oncology. 2022;40(15).
180. Belzile-Dugas E, Eisenberg MJ. Radiation-induced cardiovascular disease: Review of an underrecognized pathology. Vol. 10, Journal of the American Heart Association. 2021.
181. Apte N, Dherange P, Mustafa U, Ya’qoub L, Dawson D, Higginbotham K, et al. Cancer Radiation Therapy May Be Associated With Atrial Fibrillation. Front Cardiovasc Med. 2021;8.
182. Pedersen LN, Valenzuela Ripoll C, Ozcan M, Guo Z, Lotfinaghsh A, Zhang S, et al. Cardiac radiation improves ventricular function in mice and humans with cardiomyopathy. Med. 2023;4(12).
183. Vyas R, Changal KH, Bhuta S, Pasadyn V, Katterle K, Niedoba MJ, et al. Impact of Intramyocardial Hemorrhage on Clinical Outcomes in ST-Elevation Myocardial Infarction: A Systematic Review and Meta-analysis. Vol. 1, Journal of the Society for Cardiovascular Angiography and Interventions. 2022.
184. Betgem RP, De Waard GA, Nijveldt R, Beek AM, Escaned J, Van Royen N. Intramyocardial haemorrhage after acute myocardial infarction. Vol. 12, Nature Reviews Cardiology. 2015.
185. Wijerathne H, Langston JC, Yang Q, Sun S, Miyamoto C, Kilpatrick LE, et al. Mechanisms of radiation-induced endothelium damage: Emerging models and technologies. Vol. 158, Radiotherapy and Oncology. 2021.
186. Panés J, Anderson DC, Miyasaka M, Granger DN. Role of leukocyte-endothelial cell adhesion in radiation-induced microvascular dysfunction in rats. Gastroenterology. 1995 Jun;108(6):1761–9.
187. Bouten RM, Dalgard CL, Soltis AR, Slaven JE, Day RM. Transcriptomic profiling and pathway analysis of cultured human lung microvascular endothelial cells following ionizing radiation exposure. Sci Rep. 2021;11(1).
188. Oishi T, Yamasaki T, Baba S, Koizumi S, Sameshima T, Namba H. Acute and chronic hemorrhage from radiation-induced cavernous malformation associated with late-delayed radiation necrosis in long surviving glioma patients: A case report. Oncol Lett. 2020;19(1).
189. Mitchell JD, Cehic DA, Morgia M, Bergom C, Toohey J, Guerrero PA, et al. Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society. Vol. 3, JACC: CardioOncology. 2021.
190. Weintraub NL, Jones WK, Manka D. Understanding radiation-induced vascular disease. J Am Coll Cardiol. 2010 Mar 23;55(12):1237–9.
191. Nielsen KM, Offersen BV, Nielsen HM, Vaage-Nilsen M, Yusuf SW. Short and long term radiation induced cardiovascular disease in patients with cancer. Vol. 40, Clinical Cardiology. 2017.
192. Suzuki A, Deisher AJ, Rettmann ME, Lehmann HI, Hohmann S, Wang S, et al. Catheter-Free Arrhythmia Ablation Using Scanned Proton Beams: Electrophysiologic Outcomes, Biophysics, and Characterization of Lesion Formation in a Porcine Model. Circ Arrhythm Electrophysiol. 2020;13(10).
193. Zeppenfeld K, Rademaker R, Al-Ahmad A, Carbucicchio C, De Chillou C, Cvek J, et al. Patient selection, ventricular tachycardia substrate delineation, and data transfer for stereotactic arrhythmia radioablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society. Europace. 2025 Mar 28;27(4).
194. Neuwirth R, Cvek J, Knybel L, Jiravsky O, Molenda L, Kodaj M, et al. Stereotactic radiosurgery for ablation of ventricular tachycardia. Europace. 2019;21(7).
195. Yamani N, Abbasi A, Almas T, Mookadam F, Unzek S. Diagnosis, treatment, and management of pericardial effusion- review. Vol. 80, Annals of Medicine and Surgery. 2022.
196. Thawkar VN, Taksande K. A Comprehensive Review on Stereotactic Arrhythmia Radioablation (STAR): Pioneering a New Era in Arrhythmia Management. Cureus. 2024 Oct;16(10):e70601.
197. Chiu MH, Mitchell LB, Ploquin N, Faruqi S, Kuriachan VP. Review of Stereotactic Arrhythmia Radioablation Therapy for Cardiac Tachydysrhythmias. Vol. 3, CJC Open. 2021.
198. Kawamura M, Shimojo M, Tatsugami F, Hirata K, Fujita S, Ueda D, et al. Stereotactic arrhythmia radioablation for ventricular tachycardia: a review of clinical trials and emerging roles of imaging. J Radiat Res. 2025 Jan 22;66(1):1–9.
199. Gianni C, Rivera D, Burkhardt JD, Pollard B, Gardner E, Maguire P, et al. Stereotactic arrhythmia radioablation for refractory scar-related ventricular tachycardia. Heart Rhythm. 2020;17(8).
200. Arkles J, Markman T, Trevillian R, Yegya-Raman N, Garg L, Nazarian S, et al. One-year outcomes after stereotactic body radiotherapy for refractory ventricular tachycardia. Heart Rhythm. 2024;21(1).
201. Carbucicchio C, Andreini D, Piperno G, Catto V, Conte E, Cattani F, et al. Stereotactic radioablation for the treatment of ventricular tachycardia: preliminary data and insights from the STRA-MI-VT phase Ib/II study. Journal of Interventional Cardiac Electrophysiology. 2021;62(2).
202. Molon G, Giaj-Levra N, Costa A, Bonapace S, Cuccia F, Marinelli A, et al. Stereotactic ablative radiotherapy in patients with refractory ventricular tachyarrhythmia. European Heart Journal, Supplement. 2022;24.
203. Krug D, Zaman A, Eidinger L, Grehn M, Boda-Heggemann J, Rudic B, et al. Radiosurgery for ventricular tachycardia (RAVENTA): interim analysis of a multicenter multiplatform feasibility trial. Strahlentherapie und Onkologie. 2023;199(7).
204. Miszczyk M, Sajdok M, Bednarek J, Latusek T, Wojakowski W, Tomasik B, et al. Stereotactic management of arrhythmia - radiosurgery in treatment of ventricular tachycardia (SMART-VT). Results of a prospective safety trial. Radiotherapy and Oncology. 2023;188.
205. van der Ree MH, Dieleman EMT, Visser J, Planken RN, Boekholdt SM, de Bruin-Bon RHA, et al. Non-invasive stereotactic arrhythmia radiotherapy for ventricular tachycardia: results of the prospective STARNL-1 trial. Europace. 2023;25(3).
206. Amino M, Kabuki S, Kunieda E, Hashimoto J, Sugawara A, Sakai T, et al. Interim Report of a Japanese Phase II Trial for Cardiac Stereotactic Body Radiotherapy in Refractory Ventricular Tachycardia ― Focus on Target Determination ―. Circ Rep. 2023;5(3).
207. Chang WI, Jo HH, Cha MJ, Chang JH, Choi CH, Kim HJ, et al. Short-term and long-term effects of noninvasive cardiac radioablation for ventricular tachycardia: A single-center case series. Heart Rhythm O2. 2023;4(2).
208. Miszczyk M, Hoeksema WF, Kuna K, Blamek S, Cuculich PS, Grehn M, et al. Stereotactic arrhythmia radioablation (STAR)-A systematic review and meta-analysis of prospective trials on behalf of the STOPSTORM.eu consortium. Heart Rhythm. 2025 Jan;22(1):80–9.
209. Chin R, Hayase J, Hu P, Cao M, Deng J, Ajijola O, et al. Non-invasive stereotactic body radiation therapy for refractory ventricular arrhythmias: an institutional experience. Journal of Interventional Cardiac Electrophysiology. 2021;61(3).
210. Henkel DM, Witt BJ, Gersh BJ, Jacobsen SJ, Weston SA, Meverden RA, et al. Ventricular arrhythmias after acute myocardial infarction: A 20-year community study. Am Heart J. 2006;151(4).
211. Frampton J, Ortengren AR, Zeitler EP. Arrhythmias After Acute Myocardial Infarction. Yale J Biol Med. 2023 Mar;96(1):83–94.
212. Rymer JA, Wegermann ZK, Wang TY, Li S, Smilowitz NR, Wilson BH, et al. Ventricular Arrhythmias After Primary Percutaneous Coronary Intervention for STEMI. JAMA Netw Open. 2024 May 1;7(5):e2410288.
213. Xu X, Wang Z, Yang J, Fan X, Yang Y. Burden of cardiac arrhythmias in patients with acute myocardial infarction and their impact on hospitalization outcomes: insights from China acute myocardial infarction (CAMI) registry. BMC Cardiovasc Disord. 2024 Apr 23;24(1):218.
214. Elayi CS, Charnigo RJ, Heron PM, Lee BK, Olgin JE. Primary Prevention of Sudden Cardiac Death Early Post-Myocardial Infarction: Root Cause Analysis for Implantable Cardioverter-Defibrillator Failure and Currently Available Options. Circ Arrhythm Electrophysiol. 2017;10(6).
215. Kim YG, Choi YY, Han K Do, Min KJ, Choi HY, Shim J, et al. Premature ventricular contraction increases the risk of heart failure and ventricular tachyarrhythmia. Sci Rep. 2021;11(1).
